LTFS
PVCT

Ladenburg Thalmann Financial Services’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-214,917
Closed -$20K – 5111
2016
Q3 		$20K Buy
214,917
+212,592
+9,144% +$46.4K ﹤0.01% 3422
2016
Q2 		$0 Buy
2,325
+1,000
+75% +$380 ﹤0.01% 4968
2016
Q1 		$1K Hold
1,325
– – ﹤0.01% 4636
2015
Q4 		$1K Hold
1,325
– – ﹤0.01% 4624
2015
Q3 		$1K Hold
1,325
– – ﹤0.01% 4540
2015
Q2 		$1K Hold
1,325
– – ﹤0.01% 4602
2015
Q1 		$1K Hold
1,325
– – ﹤0.01% 4522
2014
Q4 		$1K Hold
1,325
– – ﹤0.01% 4301
2014
Q3 		$1K Sell
1,325
-12,875
-91% -$12.5K ﹤0.01% 3870
2014
Q2 		$12K Buy
+14,200
New +$17K ﹤0.01% 3003

Other funds holding PVCT

CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
HFBOT
Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Ladenburg Thalmann Financial Services's PVCT Position: Q4 2016 in Review

Ladenburg Thalmann Financial Services sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 214,917 shares — an estimated $20K sold.

Ladenburg Thalmann Financial Services first reported a position in PVCT in Q2 2014 and held it in 10 quarters. The position peaked at $20K in Q3 2016. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

  • Ladenburg Thalmann Financial Services reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 214,917 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $20K.
  • Ladenburg Thalmann Financial Services first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 10 quarters.
  • Ladenburg Thalmann Financial Services's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $20K in Q3 2016.
  • 8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2016, filed 14 Feb 2017.